Unicycive CEO Optimistic About OLC Approval
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2026
0mins
"As we approach the June 29th PDUFA target action date, we remain optimistic about the potential approval of OLC and focused on preparations for the subsequent launch of OLC," said Shalabh Gupta, Chief Executive Officer of Unicycive. "Our ongoing dialogue with the FDA during the review cycle has been constructive and timely. Uncontrolled hyperphosphatemia remains a significant health concern, affecting nearly 75% of U.S. patients with chronic kidney disease who are undergoing dialysis. OLC has the potential to improve adherence and phosphorus control with reduced pill burden, compared with currently available phosphate binders."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UNCY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UNCY
Wall Street analysts forecast UNCY stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.740
Low
21.00
Averages
35.80
High
60.00
Current: 7.740
Low
21.00
Averages
35.80
High
60.00
About UNCY
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trump's Policy Impact on Biopharma Innovation
- Global Collaboration Necessity: Acadia Pharmaceuticals CEO Catherine Owen Adams emphasized at the FTUS Pharma and Biotech Summit that while Trump's 'Most Favored Nation' policy incentivizes drugmakers to operate more in the US, global partnerships are critical for advancing R&D, highlighting the potential of scientific institutions worldwide.
- China's R&D Advantage: Unicycive Therapeutics CEO Shalabh Gupta noted that his company has established partnerships with researchers in China and South Korea, reflecting a belief that patient needs are global, and pointing to China's cost and efficiency advantages in R&D that may pose long-term competitive pressures on the US.
- US Innovation Outlook: Eric Tokat from Centerview Partners remarked that while Chinese biopharma companies were previously seen as copycats, real innovations are emerging today, stressing that the US must continue funding universities and the NIH to maintain its leadership in biopharma R&D.
- Future Treatment Prospects: Adams predicts that the first drug entirely created by AI will enter testing within the next five years, while Gupta anticipates the development of more 'one and done' therapies, indicating rapid advancements in the biopharma sector.
See More
Unicycive Therapeutics Reports Q1 Loss, Misses EPS Estimates
- Disappointing Earnings: Unicycive Therapeutics reported a Q1 GAAP EPS of -$0.54, missing estimates by $0.08, indicating challenges in profitability that may affect investor confidence.
- Cash Reserves: As of May 11, 2026, the company's unaudited cash, cash equivalents, and marketable securities totaled $57.1 million, suggesting a degree of financial flexibility to support operations in the short term.
- Sufficient Funding: The company believes it has enough resources to fund planned operations into 2027, indicating strategic planning despite current financial setbacks, which may reassure stakeholders about its operational continuity.
- Increased Market Attention: Unicycive Therapeutics presented at the 25th Annual Needham Virtual Healthcare Conference, potentially attracting more investor interest in its future developments and market opportunities.
See More
Kuehn Law Investigates Unicycive Executives for Fiduciary Breaches
- Investigation Background: Kuehn Law, PLLC is investigating whether certain officers and directors of Unicycive Therapeutics, Inc. breached their fiduciary duties to shareholders, with allegations in a federal securities lawsuit claiming the company overstated its readiness to meet FDA manufacturing compliance requirements.
- False Statement Allegations: The lawsuit asserts that insiders at Unicycive failed to disclose that their ability to satisfy FDA requirements was overstated, resulting in public statements being materially false and misleading at all relevant times.
- Shareholder Rights Protection: Kuehn Law urges shareholders who purchased UNCY stock prior to March 29, 2024, to contact the firm promptly to enforce their rights, emphasizing that shareholder voices are crucial for the integrity and fairness of financial markets.
- Legal Cost Commitment: Kuehn Law commits to covering all case costs without charging investor clients, highlighting its dedication to protecting shareholder rights and encouraging active participation to secure the future of their investments.
See More
Kuehn Law Investigates Unicycive Executives for Fiduciary Breaches
- Investigation Background: Kuehn Law, PLLC is investigating whether certain officers and directors of Unicycive Therapeutics, Inc. breached their fiduciary duties to shareholders, with allegations in a federal securities lawsuit claiming the company overstated its readiness to meet FDA manufacturing compliance requirements.
- False Statement Allegations: The lawsuit asserts that Unicycive exaggerated the regulatory prospects of the OLC NDA, resulting in public statements that were materially false and misleading at all relevant times.
- Shareholder Rights Protection: Kuehn Law urges shareholders who own UNCY stock purchased before March 29, 2024, to contact the firm promptly to enforce their rights, indicating that there may be limited time for legal action.
- Legal Service Commitment: Kuehn Law promises to cover all case costs without charging investor clients, emphasizing the importance of shareholder participation in maintaining the integrity and fairness of financial markets.
See More
Unicycive Therapeutics Reports FY Loss and Cash Position
- Disappointing Earnings: Unicycive Therapeutics reported a fiscal year GAAP EPS of -$1.67, missing expectations by $0.02, indicating ongoing challenges in profitability that may affect investor confidence.
- Cash Position: As of March 30, 2026, the company's unaudited cash, cash equivalents, and marketable securities totaled $54.9 million, suggesting a reasonable liquidity position to support operations in the near term.
- Sufficient Funding Assurance: The company believes it has adequate resources to fund planned operations into 2027, reflecting management's confidence in future growth despite current financial pressures.
- FDA Review Progress: Unicycive's resubmitted marketing application for its kidney disease drug has been granted FDA review, which could enhance its market competitiveness if successful, despite the current disappointing financial performance.
See More
ASP Isotopes Class Action Survives Dismissal Motion
- Class Action Progress: The U.S. District Court for the Southern District of New York partially denied ASP Isotopes Inc. (NASDAQ: ASPI) and its executives' motion to dismiss, allowing the securities fraud class action to proceed, indicating significant legal exposure for the company.
- False Statement Allegations: The lawsuit alleges that the company and its executives made materially false and misleading statements regarding their uranium enrichment technology prior to September 2024, raising approximately $18.6 million without actual testing, which could have long-term financial repercussions for the firm.
- Investor Rights Protection: Investors who purchased ASP Isotopes securities before September 26, 2024, can seek corporate reforms and fund recovery, suggesting that legal proceedings may provide remedies for affected investors and enhance market confidence in corporate governance.
- Future Risk Assessment: As the lawsuit progresses, ASP Isotopes may face increased regulatory scrutiny and a crisis of market trust, impacting its future financing capabilities and business development strategies, necessitating close monitoring of subsequent developments.
See More
Trump's Policy Impact on Biopharma Innovation
- Global Collaboration Necessity: Acadia Pharmaceuticals CEO Catherine Owen Adams emphasized at the FTUS Pharma and Biotech Summit that while Trump's 'Most Favored Nation' policy incentivizes drugmakers to operate more in the US, global partnerships are critical for advancing R&D, highlighting the potential of scientific institutions worldwide.
- China's R&D Advantage: Unicycive Therapeutics CEO Shalabh Gupta noted that his company has established partnerships with researchers in China and South Korea, reflecting a belief that patient needs are global, and pointing to China's cost and efficiency advantages in R&D that may pose long-term competitive pressures on the US.
- US Innovation Outlook: Eric Tokat from Centerview Partners remarked that while Chinese biopharma companies were previously seen as copycats, real innovations are emerging today, stressing that the US must continue funding universities and the NIH to maintain its leadership in biopharma R&D.
- Future Treatment Prospects: Adams predicts that the first drug entirely created by AI will enter testing within the next five years, while Gupta anticipates the development of more 'one and done' therapies, indicating rapid advancements in the biopharma sector.
See More
Unicycive Therapeutics Reports Q1 Loss, Misses EPS Estimates
- Disappointing Earnings: Unicycive Therapeutics reported a Q1 GAAP EPS of -$0.54, missing estimates by $0.08, indicating challenges in profitability that may affect investor confidence.
- Cash Reserves: As of May 11, 2026, the company's unaudited cash, cash equivalents, and marketable securities totaled $57.1 million, suggesting a degree of financial flexibility to support operations in the short term.
- Sufficient Funding: The company believes it has enough resources to fund planned operations into 2027, indicating strategic planning despite current financial setbacks, which may reassure stakeholders about its operational continuity.
- Increased Market Attention: Unicycive Therapeutics presented at the 25th Annual Needham Virtual Healthcare Conference, potentially attracting more investor interest in its future developments and market opportunities.
See More
Kuehn Law Investigates Unicycive Executives for Fiduciary Breaches
- Investigation Background: Kuehn Law, PLLC is investigating whether certain officers and directors of Unicycive Therapeutics, Inc. breached their fiduciary duties to shareholders, with allegations in a federal securities lawsuit claiming the company overstated its readiness to meet FDA manufacturing compliance requirements.
- False Statement Allegations: The lawsuit asserts that insiders at Unicycive failed to disclose that their ability to satisfy FDA requirements was overstated, resulting in public statements being materially false and misleading at all relevant times.
- Shareholder Rights Protection: Kuehn Law urges shareholders who purchased UNCY stock prior to March 29, 2024, to contact the firm promptly to enforce their rights, emphasizing that shareholder voices are crucial for the integrity and fairness of financial markets.
- Legal Cost Commitment: Kuehn Law commits to covering all case costs without charging investor clients, highlighting its dedication to protecting shareholder rights and encouraging active participation to secure the future of their investments.
See More
Kuehn Law Investigates Unicycive Executives for Fiduciary Breaches
- Investigation Background: Kuehn Law, PLLC is investigating whether certain officers and directors of Unicycive Therapeutics, Inc. breached their fiduciary duties to shareholders, with allegations in a federal securities lawsuit claiming the company overstated its readiness to meet FDA manufacturing compliance requirements.
- False Statement Allegations: The lawsuit asserts that Unicycive exaggerated the regulatory prospects of the OLC NDA, resulting in public statements that were materially false and misleading at all relevant times.
- Shareholder Rights Protection: Kuehn Law urges shareholders who own UNCY stock purchased before March 29, 2024, to contact the firm promptly to enforce their rights, indicating that there may be limited time for legal action.
- Legal Service Commitment: Kuehn Law promises to cover all case costs without charging investor clients, emphasizing the importance of shareholder participation in maintaining the integrity and fairness of financial markets.
See More
Unicycive Therapeutics Reports FY Loss and Cash Position
- Disappointing Earnings: Unicycive Therapeutics reported a fiscal year GAAP EPS of -$1.67, missing expectations by $0.02, indicating ongoing challenges in profitability that may affect investor confidence.
- Cash Position: As of March 30, 2026, the company's unaudited cash, cash equivalents, and marketable securities totaled $54.9 million, suggesting a reasonable liquidity position to support operations in the near term.
- Sufficient Funding Assurance: The company believes it has adequate resources to fund planned operations into 2027, reflecting management's confidence in future growth despite current financial pressures.
- FDA Review Progress: Unicycive's resubmitted marketing application for its kidney disease drug has been granted FDA review, which could enhance its market competitiveness if successful, despite the current disappointing financial performance.
See More
ASP Isotopes Class Action Survives Dismissal Motion
- Class Action Progress: The U.S. District Court for the Southern District of New York partially denied ASP Isotopes Inc. (NASDAQ: ASPI) and its executives' motion to dismiss, allowing the securities fraud class action to proceed, indicating significant legal exposure for the company.
- False Statement Allegations: The lawsuit alleges that the company and its executives made materially false and misleading statements regarding their uranium enrichment technology prior to September 2024, raising approximately $18.6 million without actual testing, which could have long-term financial repercussions for the firm.
- Investor Rights Protection: Investors who purchased ASP Isotopes securities before September 26, 2024, can seek corporate reforms and fund recovery, suggesting that legal proceedings may provide remedies for affected investors and enhance market confidence in corporate governance.
- Future Risk Assessment: As the lawsuit progresses, ASP Isotopes may face increased regulatory scrutiny and a crisis of market trust, impacting its future financing capabilities and business development strategies, necessitating close monitoring of subsequent developments.
See More
